Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Understanding that the medication maintains its biological activity prevents unnecessary dose escalation, protocol abandonment, or switching to alternative compounds
rather, its a demonstration product, given away and served at events
Key findings across Phase II and III trials: Women receiving PT-141 showed statistically significant increases in satisfying sexual events per month compared to placebo Reduction in sexual distress scores was observed across multiple validated instruments Effects were noted within the first treatment cycle and maintained across the 12-week study period Response was not limited to any one demographic subgroup efficacy was consistent across age ranges within the premenopausal population Research Context for Male Sexual Dysfunction While PT-141s FDA approval is specifically for HSDD in women, substantial preclinical and Phase II research has examined its effects in men particularly in cases where psychological or neurological factors contribute to sexual dysfunction that vascular agents alone cannot address
Managing side effects through rotation Some people tolerate one medication better than the other
